Final rule published

Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV

Record date · Nov 12, 2026

What this means

Status
Final rule published
What happened
On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2- methylpropan…
What to check next
The published rule gives Nov 12, 2026 as its effective date. Check the official docket for later changes.
Check the original record

About this record

On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2- methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing oveporexton, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA.

Record details

Federal Register document
2026-23075
Stated effective date
2026-11-12
Stated comment deadline
2026-12-14

Sources and related records

Source checked .